Abstract We report our experience in using flow cytometry-
Introduction
Hemophagocytic lymphohistiocytosis (HLH) is a lifethreatening disorder characterized by severe hyperinflammation. HLH is not a single disease, but a characteristic syndrome that may develop in the context of various underlying conditions [1] . Genetic diseases affecting lymphocyte cytotoxicity, in which HLH is the key manifestation, are summarized as familial HLH (FHL2-5). In other genetic conditions affecting lymphocyte cytotoxicity, HLH can be one manifestation of a more complex syndrome (Griscelli syndrome type II (GS2), Chediak-Higashi syndrome (CHS), Hermansky-Pudlak syndrome type II (HPS2)) [2] . Two additional primary immunodeficiencies, X-linked lymphoproliferative disease type I and II, are associated with a high risk of HLH, particularly following EBV infection [3] . HLH developing in any of these genetic diseases is usually termed primary (1°) HLH [4, 5] . In addition, there are Bsecondary( 2°) or Bsporadic^forms of HLH, frequently induced by infections, in the absence of a biallelic or hemizygous defect in a gene associated with 1°HLH. 2°HLH also occurs in malignant, autoinflammatory, or autoimmune diseases, frequently also triggered or enhanced by infections [6] . Finally, 2°HLH occurs in genetic diseases, in which HLH is a rare, but nevertheless associated manifestation. This includes primary immunodeficiencies (PID) [7] and metabolic diseases [6] .
The distinction between 1°and 2°HLH has important clinical implications because most patients with 1°HLH require hematopoietic stem cell transplantation (HSCT) [8] [9] [10] [11] . Rapid identification of 1°HLH patients is paramount to facilitate immediate initiation of HSCT preparation. We and others have previously demonstrated the high sensitivity and specificity of intracellular protein staining and NK-cell and cytotoxic T cell (CTL) degranulation testing for identifying patients with 1°HLH [12] [13] [14] [15] . However, to which extent these tests can be used in clinical practice to reduce genetic screening, to direct more extensive genetic analysis including exome sequencing, or to expedite diagnosis has not been explored. Moreover, a recent paper speculated that with increased use of high throughput sequencing, immunological tests might be fully abandoned [16] . Thus, the significance of immunological evaluation of HLH patients remains debated.
We prospectively analyzed whether immunological studies can be used as a decision tool for the need and extent of genetic studies in 290 children referred for suspected HLH to the German HLH reference centers. Immunological screening performed before targeted sequencing of HLH-associated genes led to substantial reduction of genetic investigations and provided direct validation of the functional relevance of genetic findings. It was also used to identify patients with indication for whole exome sequencing (WES) on the basis of clear functional abnormalities, which helped resolve a few additional cases. This clinical practice provided functionally relevant information for treatment intensity and decisions on HSCT in patients with suspected HLH within 72 h. It has contributed to a significant reduction in the time from HLH diagnosis to HSCT in patients with primary HLH.
Methods
The German HLH Study
The HLH study group of the Society for Pediatric Oncology and Hematology in Germany, Austria, and Switzerland (GPOH) is coordinated by two reference centers (Hamburg and Freiburg). About 80-90% of children with suspected HLH in German hospitals are reported. Children with macrophage activation syndrome (MAS) in autoimmune or autoinflammatory diseases are usually only reported following hematological consultation for exclusion of 1°HLH or specific treatment issues.
Patient Cohort
All patients below age 16 reported to the HLH study for suspected HLH between 01/2010 and 12/2014 were included. Twenty international patients, mainly from Turkey and Eastern Europe, were included into the analysis of the diagnostic algorithm, but excluded from epidemiological calculations. Informed consent was obtained according to the institutional review board approval (University of Freiburg ethics committee's protocol numbers 143/12 and 40/08).
Clinical Patient Classification
Patients were classified as follows: (1) patients fulfilling at least 5/8 clinical criteria for HLH (Bfull^HLH), (2a) patients with sufficient documentation to state that they fulfilled less than 5/8 criteria (Bincomplete HLH^), (2b) patients with liver failure or inflammatory CNS disease which are no formal HLH criteria, but prompted evaluation for 1°HLH (Batypical HLH^), (3) patients without any HLH symptoms, referred because of an affected relative or albinism. Of these, we included only those with a final 1°HLH diagnosis (Basymptomatic genetic disease^), (4) patients with insufficient documentation to state whether they fulfilled 5/8 criteria (Bincomplete clinical information^). This mostly concerned patients referred for immunological screening, for which Bincomplete/atypical^HLH was a remote differential diagnosis. In these patients, the referring physicians had frequently not quantified all HLH criteria at the time of requesting immunological analysis, which did not allow judgment, whether at least 5/8 criteria were fulfilled. Once provided with the negative immunological results, other diagnoses were pursued and outcome of further lab tests and final patient diagnosis were not reported to the HLH study group, leading to incomplete documentation. Among 388 patients referred for immunological evaluation in the study period, 98 patients were in this category leaving 290 patients for analyses.
Immunological Studies and Genetic Analyses
Degranulation assays with Bfresh^(uncultured) and Bactivated^(incubated with 100 U/ml IL-2 for 48-72 h) NK cells were performed as published using protocol 1 [12] . Tests were repeated if the day control did not yield normal results. Results were classified as normal (fresh assay > 10% or fresh assay < 10% and activated assay > 35%) or defective (fresh assay < 10% and activated assay < 35%) based on previously published receiver operating characteristic analyses. In patients with abnormal protein stains, genomic DNA was Sanger sequenced for mutations in PRF1 (FHL-2), SH2D1A (XLP-1), or BIRC4A (XLP-2). Patients with abnormal or defective degranulation were analyzed in parallel for mutations in UNC13D (FHL-3), including selected intronic regions [17, 18] , and STXBP2 (FHL-5), followed by analysis of STX11 [19] . In patients with albinism, hair morphology and blood smear abnormalities guided the order of sequencing of RAB27A (GS-2), LYST (CHS), and AP3B1 (HPS2). In the course of the study, we changed our policy and sequenced RAB27A also in patients without these manifestations [20] . Primer sequences are available upon request (U. zur Stadt). Exome sequencing was performed in unresolved cases with defective fresh NK degranulation as described [21] . Selected variants were confirmed by Sanger sequencing.
Final Patient Classification
Genetic variants were considered disease-causing (1°HLH), if they occurred in a homozygous, compound heterozygous, or hemizygous X-linked form and were shown to be functionally relevant by protein expression and/or functional analysis and/or had been published as HLH-associated in another patient. For patients with BfullĤ LH, we obtained follow-up information on survival, relapse of HLH and final diagnostic classification by the treating physician. Patients with a definite diagnosis of rheumatic disease, malignancy, metabolic disease, or PID were classified as such independent of the time of followup. Patients with HLH only associated with infection or HLH of unclear cause were classified as 2°HLH, if they lacked relapse within a follow-up period of at least 6 months.
Time to Transplant Analysis
To test whether time from clinical (not genetic) diagnosis of HLH to HSCT had changed after the introduction of immunological screening, we compared the study period (2010-2014) to a previous 5-year period (2003) (2004) (2005) (2006) (2007) (2008) . For this, a competing risk analysis was performed with death prior to HSCT as competing event, using R 3.1.0 (R Foundation for Statistical Computing, Vienna Austria) [22] .
Patients of the study cohort (2010-2014) with a diagnosis of primary HLH who received an HSCT or died prior to HSCT were included in the analysis (n = 38). Patients consecutively diagnosed with primary HLH between 2003 and 2008 were used for comparison (n = 38). However, in this cohort, we only included patients with a genetic defect that was known at the time of diagnosis (leading to exclusion patients with a retrospective diagnosis of FHL5). Patients diagnosed in 2009 were not included as diagnostic procedures were gradually modified during that year. Patients from outside Germany, asymptomatic patients, and patients with XIAP deficiency were excluded in both groups.
Results

Patient Cohort and Clinical Classification
We analyzed 290 patients referred between January 2010 and December 2014. This included 162 patients with Bfull HLH^ (Fig. 1 ) and 111 patients with Bincomplete HLH^or atypical HLH (CNS inflammatory disease or liver failure) (Fig. 2) . We included 17 patients with asymptomatic genetic disease.
High Success Rate for FHL-2, XLP-1, and XLP-2 by Flow Cytometry Screening
All patients were screened by flow cytometry for perforin expression and male patients also for SAP or XIAP expression. Seven patients had reduced ( Sanger (7) Sanger (12) WES (1) abnormal (51) WES (2) normal (142)+2 n.d. (6) mutation 2
Sanger (4)
2 A91V 1 the patients with a final diagnosis of FHL-2, XLP-1, or XLP-2 had normal protein expression (Fig. 3 , left panels).
Effective Functional Screening for Genetic Degranulation Deficiency in Patients with BFull^HLH
Sixty-six patients with Bfull^HLH (41%) had fresh NK degranulation < 10%. In 60 of these, we performed additional degranulation testing of PHA/IL-2 stimulated NK cells, while lack of material did not allow further tests in 6 patients (Fig. 2) . Among the 47 patients with 0-5% fresh NK degranulation, analysis of stimulated NK cells led to classification as Bdefective degranulation^in 39 (abnormal + not done). All but 2 of these patients (with a diagnosis of LCH and anaplastic lymphoma) were sequenced, leading to a genetic diagnosis in 32/37 patients. Among the 19 patients with 5-10% fresh NK degranulation (Fig. 4 ), 11 were classified as Bdefective degranulation^(abnormal + not done), 7 of these were sequenced, and mutations were found in 4. Four patients were not sequenced because of a diagnosis of SCID (1), lymphoma (2) , and lack of material (1). Overall, Sanger sequencing revealed disease-causing mutations in 34/44 patients with defective degranulation. Seventy-two of the 142 patients with Bfull^HLH and normal protein expression (51%) also had normal fresh NK degranulation, while this test was not performed in 6 patients (Fig. 1, Fig. 4) . In one patient, sequencing was performed because of albinism and pathologic hair pigment distribution revealed a diagnosis of CHS (details below). Among the other 71 patients, no genetic analysis was performed in 48, while 70 genes were sequenced in 23 patients because of the request of the referring physician. The monoallelic A91V perforin mutation was detected in one patient with Langerhans cell histiocytosis and EBV infection, and in one patient with genetically confirmed osteopetrosis. All 71 patients were classified as 2°HLH or as lost to follow-up on the following basis: 7 patients died in the acute phase of HLH, 3 of them in the context of malignant disease, 2 with syndromic diseases, and 2 in the context of EBV infection with negative genetic results. One patient had CGD. Another 53 patients had a follow-up of > 6 months (median 2.4 years, range 6 months to 4 years) without relapse. The remaining 11 patients (3 with MAS) were lost to follow-up.
The 12 patients who were not sequenced and the 18 patients with negative genetic results were classified as 2°H LH or lost to follow-up on the following basis: 5 patients died, 3 from malignant disease, 1 from Wolman disease, and one from unknown cause (Sanger sequenced in all known HLH-associated genes). One patient had SCID. Twenty-two patients had no disease recurrence within a median of 1.6-year follow-up (range 0.7-4.9 years). One patient had a second HLH episode 2 years later but no mutation in known genes, while one patient was lost to follow-up.
The Use of Degranulation Assays for Rational Genetic Testing in Patients with BIncomplete/Atypical^HLH
In the group with Bincomplete/atypical^HLH, 7 of 111 patients had reduced or absent expression of PRF1 (1), SH2D1A (2), or XIAP (4) (Fig. 2) . Fresh NK degranulation was analyzed in 100 of the remaining 104 patients, with a normal result in 79 (79%) (Fig. 2, Fig. 5 ). In 26 of these, 52 genetic tests were performed based on requests by the referring physicians. All were negative. Twenty-five patients had fresh NK degranulation between 5 and 10% (Fig. 5) . In patients with abnormal stimulated NK/CTL degranulation and 0/8 patients where this second test was normal (Fig. 5) . Table 1 shows details of the patients with Bincomplete/atypical^presen-tation in whom genetic testing revealed 1°HLH. no Sanger SangerSanger + S a n g e r + S a n g e rn o S a n g e r S a n g e r + S a n g e rn o S a n g e r 
Exome Sequencing Uncovers Additional Patients with 1°HLH
Patients with defective fresh NK degranulation (< 5%), but no mutations in 1°HLH genes upon Sanger sequencing qualified for WES. In 12 of 20 patients fulfilling these criteria (Figs. 4 and 5) , WES was not performed because there was insufficient material, the family denied consent or because the physician did not want to pursue this option because a plausible diagnosis such as malignancy or metabolic disease had been made (suppl. Tab. 2). Using WES, a genetic diagnosis could be established in four patients from consanguineous families ( Table 2 ). In one patient with Bfull^HLH, we detected an unknown homozygous inversion of 1.65 MB involving the gene UNC13D with intronic breakpoints. This mutation had been missed in the conventional sequencing procedure based on amplification of single exons, which had rendered normal PCR products and sequences. Using WES, the breakpoints of this new inversion were assigned to intron 25 of UNC13D, 110 bp downstream of exon 25, and intron 3 of TTYH2. A Western blot analysis revealed complete absence of the Munc13-4 protein (Suppl. Fig. 1 ), confirming FHL-3. The second patient with Bfull^HLH had the homozygous mutation c.553delT resulting in a frame shift in the gene encoding lysosomal acid lipase (LIPA) and was diagnosed with Wolman disease, which is known to sometimes present with an HLH phenotype [23] . 1°HLH was also diagnosed in two patients with Bincomplete/atypical^HLH. This included one patient with GS-2, in whom RAB27A had initially not been sequenced because he lacked albinism and hair abnormalities. The second patient carried a biallelic deletion in the gene encoding AP-3δ. This patient was given the novel diagnosis of HPS-10; details were reported elsewhere [21] . In four non-consanguineous patients with Bfull^HLH, analysis of WES data did so far not yield a plausible candidate gene. (Fig. 6a) . This included 12 patients with rheumatic disease, 11 with malignancy, one patient each with common γ-chain deficiency, X-linked chronic granulomatous disease and prolidase deficiency, and 38 patients in whom an infection was the only associated clinical feature. In 28 patients, no clear underlying condition was found. Eleven patients (8%) were lost to follow-up. Notably, 1°HLH was also diagnosed in 32 patients in the absence of Bfull^HLH (Fig. 6b ). Of these, 15 (5 FHL) had Bincomplete/atypical^HLH and 17 (6 FHL) were asymptomatic at the time of genetic diagnosis. This means that no more than 64% of patients with a genetic disease predisposing to HLH (80% of patients with FHL2-5) were actually diagnosed in a disease episode fulfilling the clinical HLH criteria. Among patients with 1°HLH ( Fig. 6c) , FHL represented 64% with predominance of FHL-3 (29%), followed by FHL-5 (17%) and FHL-2 (16%). Albinism syndromes were diagnosed in 20% of patients, while 16% had XLP. This distribution was similar if the analysis was restricted to the 81 patients referred from German hospitals (not shown).
Immunological Screening Contributes to More Rapid HSCT in Patients with 1°HLH
To test whether time from clinical diagnosis of HLH to HSCT had changed after the introduction of immunological screening, we compared the study period (2010-2014) to a previous 5-year period (2003) (2004) (2005) (2006) (2007) (2008) . Time from clinical diagnosis of acute HLH to HSCT was significantly shorter in the time period after introduction of the screening algorithm (median 130 versus 206 days, p = 0.007, corrected for death prior to HSCT as competing event) (Fig. 7) .
Discussion
In recent years, new diagnostic procedures have significantly changed the approach to patients with suspected HLH [24] . Identification of novel HLH-associated genes has improved possibilities to definitely diagnose 1°HLH [19, 25, 26] . More specific immunological tests facilitate rapid identification of patients in need of HSCT [12] . In addition, next-generation sequencing (NGS) allows more comprehensive genetic analyses while offering opportunities to identify novel genes predisposing to HLH [27] . Hence, diagnostic approaches are changing, and the most efficient algorithm remains controversial. Here, we prospectively evaluated the use of immunological screening as a decision tool for genetic studies including WES. The guiding principle was to provide the most rapid, reliable, and efficient basis for HSCT indication and other treatment decisions in patients with suspected HLH. We performed three-step immunological screening with intracellular protein staining and fresh NK degranulation followed by activated NK degranulation in patients with abnormal results. We have previously shown that the fresh NK assay has excellent sensitivity (96%) and satisfying specificity (88%) [12] . Although both parameters are slightly inferior with activated NK degranulation [12] , this second test improves the positive predictive value and was therefore added to guide our decision on sequencing in this study. We did not perform parallel cytotoxicity assays because of previously discussed limitations [12] . We did not sequence the perforin gene in patients with normal protein expression based on long-term experience in our and several other laboratories (K. Gilmour, Y. Bryceson, G. de Saint Basile, personal communication). In contrast, patients with a strong clinical suspicion for XLP were further analyzed despite normal protein expression. This included NKT cell quantification for XLP1 [28] and L-18 MDP stimulation for XLP2 [29] , followed by genetic analysis in those patients, where high suspicion remained. Among 162 patients with Bfull^HLH in this study, 58 patients had genetic disease. Our screening approach missed one patient with atypical CHS. It can be argued that the limited follow-up of the patients with Bfull^HLH (mean of 2.4 years) is not sufficient to exclude that some patients carry clinically relevant mutations and this remains a caveat. Among 111 patients with Batypical/incomplete^HLH, 15 had genetic disease. All of them were picked up by our screening approach. These findings confirm the excellent sensitivity of immunological screening but also show that it is not 100%.
It has been suggested that because of this limited sensitivity, all patients with suspected HLH should undergo extensive sequencing. Such recommendations do not consider the limitations of genetic analyses. Thus, Bhidden^intronic mutations or inversions or mutations in genes so far not associated with HLH but affecting the same pathway are not picked up with conventional genetic analysis. This leads to no better sensitivity of genetic compared to immunologic analysis. Moreover, extensive sequencing, in particular in the poorly defined cohort of patients with Bincomplete^HLH, will generate many findings that are difficult to interpret in the absence of immunological data (such as monoallelic mutations). Restricting extensive sequencing efforts to patients with BfullĤ LH is also a questionable approach. In our study, 20% of patients with genetic disease did not present with this Bclassical^phenotype.
Overall, it is part of sound medical reasoning that any laboratory test (including genetics) has limitations and must be performed and interpreted in a clinical context. In light of the above considerations, immunological screening appears a rational approach to determine the need and the depth of sequencing in patients referred for evaluation for HLH. Earlier detection of primary HLH is a further strong argument for the use of the screening tests. We could demonstrate that the time from clinical diagnosis of HLH to HSCT was significantly shorter after the introduction of flow cytometric screening. There are certainly other factors that have accelerated the time to HSCT in recent years. However, since unambiguous abnormal screening results prompt initiation of HLA analysis and consecutive donor search within 72 h after diagnosis, we are convinced that our screening algorithm has contributed to this improvement.
Among those patients, where we performed genetic analysis, we detected biallelic or hemizygous mutations in 35% of patients with Bfull^HLH. This is similar to the Italian and Swedish cohorts [16, 30] . However, compared to the Italian cohort, FHL-2 was less frequent, while albinism syndromes and FHL-3 were more frequent. Notably, 33/91 patients (36%) with 1°HLH were not diagnosed in the context of a clinical episode fulfilling HLH criteria. This included 18 patients diagnosed in the absence of inflammatory manifestations and 15 patients diagnosed in the context of atypical/incomplete HLH. This further supports the repeatedly suggested revision of diagnostic criteria for HLH. The criteria should allow a diagnosis of 1°HLH in oligo-or asymptomatic patients in the context of immunological findings.
In patients with abnormal immunological screening, but no mutations found in the relevant genes and a suggestive clinical context, we extended our genetic analysis to WES. We identified one patient with a novel inversion in UNC13D. Due to intronic breakpoints, this mutation had not been identified by Sanger sequencing. In one patient, absence of albinism was the basis for not sequencing RAB27A. We learned during this study that this should be included, as albinism is not necessarily present in GS-2 patients [20] . We also diagnosed one metabolic disease, Wolman disease [23] . Degranulation was low in that patient while it was normal in her sister with the same mutation. It remains unclear whether degranulation testing is useful in screening for this disease; however, we had another Wolman patient with reduced degranulation mentioned in a previous paper [12] . Only one patient was diagnosed with a new disease associated with impaired cytotoxicity, HPS10 [21] . Together with the findings of the Italian study [16] , where 92% of patients with likely FHL received a genetic diagnosis, this supports the assumption that at least in European cohorts, most genes associated with impaired cytotoxicity that are linked to an HLH phenotype in humans have been discovered.
Our focus on functional screening may have led to underdiagnosis of monoallelic mutations. In the Italian study, 15% of patients with 2°HLH had monoallelic mutations in HLHassociated genes [16] . A similar frequency of monoallelic mutations was observed in a smaller Swedish cohort [30] , but such monoallelic variants were not enriched compared to healthy individuals. Furthermore, parents or siblings with monoallelic mutations do not seem to have a predisposition to HLH, although a slightly increased risk of gynecological tumors has recently been demonstrated [31] . Particularly, there is little evidence to indicate that patients carrying monoallelic mutations have a transplant indication. This important question requires clear guidance. Based on the available evidence, it is our policy that in the absence of significant functional alterations [32] , monoallelic mutations do not justify transplantation. This extends to the recommendation not to transplant after a first HLH episode in patients with homozygous A91V mutations [33, 34] . Equally, we consider carrier relatives as suitable stem cell donors and prefer a matched sibling with a monoallelic mutation without functional abnormalities to an unrelated wild-type donor.
Obviously, diagnostics of monogenic diseases is a field in transition. It has been hypothesized that NGS will soon allow rapid differentiation of 1°HLH from 2°HLH obviating the need for immunological tests [16] . We argue that this will depend on whether this approach will become rapid enough for a transplant decision. It will require fast workflows for individual samples that are cost-effective. Moreover, without functional validation, the significance of some genetic alterations including monoallelic mutations remains unclear [35] , in particular in the absence of comprehensive and well-curated mutation databases with clinical annotations. We therefore conclude that establishment of reference centers for the immunological evaluation of patients with suspected HLH is still a relevant investment into the future.
